These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32036779)

  • 1. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Wu J; Li W; Zheng Z; Lu X; Zhang H; Ma Y; Wang R
    J Biomol Struct Dyn; 2021 Mar; 39(4):1174-1188. PubMed ID: 32036779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation.
    Liu WS; Wang RR; Li WY; Rong M; Liu CL; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Jun; 38(9):2509-2520. PubMed ID: 31258001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
    Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
    Elife; 2022 May; 11():. PubMed ID: 35535491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
    Song Y; Zhao M; Wu Y; Yu B; Liu HM
    Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation.
    Li WY; Ma Y; Li HX; Lu XH; Du S; Ma YC; Zhou L; Wang RL
    Bioorg Chem; 2020 Dec; 105():104391. PubMed ID: 33113413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain-of-Function SHP2 E76Q Mutant Rescuing Autoinhibition Mechanism Associated with Juvenile Myelomonocytic Leukemia.
    Rehman AU; Rafiq H; Rahman MU; Li J; Liu H; Luo S; Arshad T; Wadood A; Chen HF
    J Chem Inf Model; 2019 Jul; 59(7):3229-3239. PubMed ID: 31244092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
    Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
    Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
    Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Satheeshkumar R; Zhu R; Feng B; Huang C; Gao Y; Gao LX; Shen C; Hou TJ; Xu L; Li J; Zhu YL; Zhou YB; Wang WL
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127170. PubMed ID: 32273218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.
    Li HL; Ma Y; Zheng CJ; Jin WY; Liu WS; Wang RL
    J Biomol Struct Dyn; 2018 Nov; 36(14):3856-3868. PubMed ID: 29125030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SHP2 phosphatase in hematological malignancies.
    Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
    Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
    Tang K; Jia YN; Yu B; Liu HM
    Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
    Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
    J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Biological Function of SHP2 in Human Disease].
    Li SM
    Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics.
    Wang RR; Ma Y; Du S; Li WY; Sun YZ; Zhou H; Wang RL
    Comput Biol Chem; 2019 Feb; 78():133-143. PubMed ID: 30508783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
    Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.